1 / 9

Healthcare

The report provides an overview of the therapies for Multiple Myeloma (Newly diagnosed - NDMM and relapsed/ refractory - RRMM), unmet need, and limitations of the current standard of care (SoC) for relapsed and refractory MM pts. The report highlights the competition and commercial opportunity in pursuing this therapy area

guest100848
Download Presentation

Healthcare

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Global Pharmaceutical & Biotechnology Outlook 2014: Rising Stars One-Stop Shop for Business Information

  2. Summary The report provides an overview of the therapies for Multiple Myeloma (Newly diagnosed - NDMM and relapsed/ refractory - RRMM), unmet need, and limitations of the current standard of care (SoC) for relapsed and refractory MM pts. The report highlights the competition and commercial opportunity in pursuing this therapy area – Comprehensive list of the early and late stage drugs in the clinic, their MoA and the companies developing them. Detailed financial and competitive analysis of the companies leading in this field for this indication – Celgene, Amgen (post-acquisition of Onyx pharma), and MorphoSys are available within this full report. Key M&A activities that have taken place in this area in the last 5 years and a list of products in early /late-stages of development available for in-licensing are highlighted in the report.

  3. This report is built using primary and secondary research data and in-house proprietary database. Reasons to buy the reportUseful for investors, Scientists, Business development managers of Pharma companies with focus in oncology to address the following-• What are the opportunities or new approaches to be deployed in the R&D of the company?• List of validated and new targets • In-licensing opportunities – Is the way to go forward and be in the race?• Commercial opportunity and companies’ valuation.

  4. - Demand volume forecasts for the major end-user applications, highlighting trends and volume share analysis for each of these applications in all major countries- Pricing forecasts and analysis of the major countries and regions- Capacity share analysis of the key producers in all the major countries- The acetic acid import and export trends in all major countries- The acetic acid installed capacity for 2010-2016 in all major regionsReasons to buy- Understand regional market dynamics through detailed demand and production forecasts, end-use data and competitive landscape analysis - Understand the differing pricing dynamics between various regions and countries

  5. KEY POINTS DISCUSSED IN THE REPORT• Overview of the Disease and Unmet need• Drugs in the pipeline: NDMM & RRMM – Mechanism of Action (MoA) and Clinical Stage of development  Comparative Clinical data of Late-stage Pipeline in RRMM and NDDM  Ongoing Clinical trial Details of Key Drugs in Pipeline• Key milestones• MPA view on the Future of the drugs in the late-stage pipeline Launch Timeline and Commercial Opportunity of Late-stage pipeline M&A and Licensing deals in the last 5 years In-licensing and/or M&A Opportunity • Detailed Company analysis includes Clinical data of drugs, Milestones, and Valuation – Amgen (AMGN), Celgene (CELG), and MorphoSys (MOR)

  6. Table Of Contents • Executive Summary • Investment Drivers of The Select Companies Covered • Multiple Myeloma (MM) • Novel Targets including Monoclonal Antibodies And Small Molecules Offer In-Licensing Opportunity • Ongoing Clinical Trial Details of Key Drugs in the Pipeline • Key Milestones • MPA View on the Future of the Drugs in the Late-Stage pipeline • Detailed Company Analysis (incl. Clinical Data of Drugs, Milestones, and Valuation)

  7. Related Reports • United States Pharmaceuticals and Healthcare Report • Puerto Rico Pharmaceuticals and Healthcare Report • Myanmar Pharmaceuticals and Healthcare Report • Estonia Pharmaceuticals and Healthcare Report • North American Healthcare Cloud Computing Market by Applications (EMR, PACS, RIS, RCM, APB), Deployment (Private, Public, Hybrid), Service (SAAS, IAAS), Pricing (Pay-As-You-Go, Spot) & End Users (Provider, Payers) - Forecast to 2018

  8. Custom Research Incase the reports don’t match your requirement then we can do a Custom Research for you. Our multifarious capabilities, cross-sector expertise and detailed knowledge of various markets, put us at a unique position to take up Custom Research demands of yours. We provide the specifications of the custom research job to a dedicated team comprising of researchers, analysts and industry experts, who have close experience and understanding of global markets, competitive landscapes, various business models, market shares, drivers, restraints and benchmarks.

  9. To know more :Treating Refractory Hematological Malignancies - Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A Contact Us:-Call India: +91-22-27810772/73 Call USA/Canada (Toll Free): 1-866-279-8368 Email id : info@bharatbook.com

More Related